The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PGNY | -20.36% | -56.91% | -15.5% | +10% |
| S&P | +18.89% | +78.8% | +12.32% | +127% |
Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.
Is the CEO's latest purchase a buy signal for investors?
Progyny generates nearly $200 million in free cash flow annually and holds over $300 million in cash, yet it has a market cap of only $1.9 billion. It could be a bargain as stock-based compensation dwindles.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $318.40M | 6.7% |
| Gross Profit | $76.88M | 21.2% |
| Gross Margin | 24.15% | 2.9% |
| Market Cap | $2.21B | 50.7% |
| Market Cap / Employee | $2.59M | 0.0% |
| Employees | 856 | 25.9% |
| Net Income | $12.49M | 18.5% |
| EBITDA | $16.59M | -0.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $112.24M | -30.9% |
| Accounts Receivable | $220.29M | -6.4% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $24.00M | 46.2% |
| Short Term Debt | $3.73M | 30.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 8.59% | 0.7% |
| Return On Invested Capital | 16.61% | 4.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $48.59M | -3.3% |
| Operating Free Cash Flow | $54.20M | 3.9% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 39.43 | 37.35 | 34.07 | 39.34 | 28.91% |
| Price to Book | 4.52 | 4.03 | 3.59 | 3.95 | 12.73% |
| Price to Sales | 1.64 | 1.59 | 1.53 | 1.78 | 35.67% |
| Price to Tangible Book Value | 4.70 | 4.28 | 3.79 | 4.15 | 13.61% |
| Price to Free Cash Flow TTM | 10.19 | 10.37 | 10.04 | 11.98 | 35.67% |
| Enterprise Value to EBITDA | 69.94 | 66.33 | 71.27 | 121.47 | 52.68% |
| Free Cash Flow Yield | 9.8% | 9.6% | 10.0% | 8.3% | -26.29% |
| Return on Equity | 10.1% | 10.9% | 11.4% | 12.5% | 11.99% |
| Total Debt | $28.90M | $28.63M | $28.15M | $27.73M | 43.87% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
